CD4 and breast carcinoma: To investigate this possibility, the TCR repertoire of MAMI-reactive IFNγ+CD4+Teff was compared to the TCR pool of total CD4+Treg in PB of five breast cancer patients with mammary gland adenocarcinoma (MaCa).